Rare Neurological Disease Treatment Market Outlook (2022 to 2032)
Majority of rare diseases at present have none or little effective procedures of diagnosis & treatment, which can be partly attributed to absence of funding toward researches on rare disease pathogenesis and lack of representative patients. Rare neurological disease are among major types of rare diseases with ineffective diagnoses and treatment options. According to WHO, 1 in 10 individuals are expected to be diagnosed with rare neurological disorder in their lifetime. Brain diseases are considered to be one of the major determinants of the neurological disease prevalence worldwide, with early intervention being the only key to prevent or curtail long-term morbidity and relevant healthcare costs.
However, diagnosis of rare neurological diseases entails several barricades including lack of intelligence and awareness about such diseases within the common medical community. This has further resulted into delayed diagnosis, and sometimes misdiagnosis, as highlighted in the book about rare diseases compiled by European Organization for Rare Diseases (EURORDIS), co-funded by European Commission. According to the publication, patients suffering from rare neurological diseases experience challenges in accessing treatment services on the coattails of lack of referral.
Spreading awareness about these diseases along with increasing their visibility are key initiatives taken by various governments worldwide for speeding up diagnostic processes and provide affected families with access to proper counselling and treatment options.
A recently published report of Future Market Insights foresees the global rare neurological disease treatment market to record a spectacular growth between the period 2022 and 2032. Revenues from treatment of rare neurological disorders worldwide are poised to surpass US$ 19,795.14 Million by 2032-end.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
North America to Remain Largest Revenue Contributor to the Market
In North America, rare neurological conditions are considered to a major healthcare concern, although fewer individuals are currently affected by the disease. Complexity of these diseases, along with their inadequacy in treatment options have led to disproportionate share of spending in healthcare. Drug companies in North America are conducting robust researches in rare diseases, however they face difficulties related to cost of treatment development related to small or geographically dispersed populations.
Government and healthcare institutes in North America are therefore collaborating to develop a robust research network, in order to facilitate data sharing, enrollment in trials & studies, and advancement in rare diseases. This will further influence the rare neurological disease treatment market in North America. The report estimates North America to remain the largest revenue contributor to the market.
Discrepancies in Research and Development Funding for Rare Neurological Disease Linked with Shortage in Healthcare Provision
Management of rare neurological diseases and provision of effective therapies represent an economic and social burden on several nations. Treatment options for patients affected with rare neurological conditions continue to be limited. Discrepancies in funding for Research and Development associated with treatment & prevention of these diseases is mainly linked with shortfall in the healthcare provision that reflects both shortage of material sources and suboptimal training exercises of clinicians apropos brain disorders.
Although there have been notable advancements in treatment of rare neurological diseases, these are not completely curative. Governments across the globe are therefore making significant improvements in their healthcare systems to render their management to be multidisciplinary, holistic, and to include supportive and palliative care. Establishing centers of expertise, which specialize in diagnosis, treatment & care of patients affected from rare neurological diseases, is a key focus area for most of the developed and developing countries across the globe.
Key players fuelling growth of the global rare neurological disease treatment market, as identified by the report, include Pfizer Inc., Allergan Plc, Novartis AG, Bayer Aktiengesellschaft, Medtronic Plc, Sanofi, Johnson & Johnson, and Teva Pharmaceutical Industries Limited.
Personalize your report by choosing insights you need and save 40%!
Frequently Asked Questions
What is the Key Trend in the Rare Neurological Disease Treatment Market?
Rising awareness regarding the spread of neurological diseases fuels the market.
What Opportunities Await the Market Players?
Significant improvement in the healthcare system boosts the market.
Who are the Leading Market Players?
Novartis AG, Pfizer Inc., and Allergan Plc are the leading market players.
Which Region is Dominating the Industry?
North America is dominating the industry.
What is the Predicted Valuation of the Market by 2032?
The market is likely to surpass US$ 19.795 million by 2032.
Table of Content
1. Global Economic Outlook2. Global Market - Executive Summary3. Global Market Overview
3.1. Introduction
3.1.1. Global Market Taxonomy
3.1.2. Global Market Definition
3.2. Global Market Size (US$ Million) and Forecast, 2022 to 2032
3.2.1. Global Market Y-o-Y Growth
3.3. Global Market Dynamics
3.4. Supply Chain
3.5. Cost Structure
3.6. USA, EU & Japan Orphan Designations per Year & Cumulative (2017 to 2021)
3.7. Worldwide Top 20 Orphan Drug Manufacturers (2022 to 2032)
3.8. Wheel of Fortune
3.9. Rare Disease Key Regulations
3.9.1. Rare Disease Key Regulations: North America
3.9.2. Rare Disease Key Regulations: Latin America
3.9.3. Rare Disease Key Regulations: Europe
3.9.4. Rare Disease Key Regulations: Asia Pacific
3.9.5. Rare Disease Key Regulations: Middle East & Africa
3.10. Forecast Scenario
3.11. PEST Analysis
3.12. Porte's Five Forces Analysis
3.13. Market Positioning and Behavioral Assessment
3.14. Investment Feasibility Assessment
3.15. Competitor Market Footprint Matrix
3.16. Key Participants Market Presence (Intensity Map) By Region
4. Global Market Analysis and Forecast 2022 to 2032
4.1. Global Market Size and Forecast By Indication, 2022 to 2032
4.1.1. Alzheimer’s Disease Market Size and Forecast, 2022 to 2032
4.1.1.1. Revenue (US$ Million) Comparison, By Region
4.1.1.2. Market Share Comparison, By Region
4.1.1.3. Y-o-Y growth Comparison, By Region
4.1.2. Narcolepsy Market Size and Forecast, 2022 to 2032
4.1.2.1. Revenue (US$ Million) Comparison, By Region
4.1.2.2. Market Share Comparison, By Region
4.1.2.3. Y-o-Y growth Comparison, By Region
4.1.3. Multiple Sclerosis Market Size and Forecast, 2022 to 2032
4.1.3.1. Revenue (US$ Million) Comparison, By Region
4.1.3.2. Market Share Comparison, By Region
4.1.3.3. Y-o-Y growth Comparison, By Region
4.1.4. Amyotrophic Lateral Sclerosis Market Size and Forecast, 2022 to 2032
4.1.4.1. Revenue (US$ Million) Comparison, By Region
4.1.4.2. Market Share Comparison, By Region
4.1.4.3. Y-o-Y growth Comparison, By Region
4.1.5. Other Indications Market Size and Forecast, 2022 to 2032
4.1.5.1. Revenue (US$ Million) Comparison, By Region
4.1.5.2. Market Share Comparison, By Region
4.1.5.3. Y-o-Y growth Comparison, By Region
4.2. Global Market Size and Forecast By Drug Type, 2022 to 2032
4.2.1. Biologics Market Size and Forecast, 2022 to 2032
4.2.1.1. Revenue (US$ Million) Comparison, By Region
4.2.1.2. Market Share Comparison, By Region
4.2.1.3. Y-o-Y growth Comparison, By Region
4.2.2. Organic Compounds Market Size and Forecast, 2022 to 2032
4.2.2.1. Revenue (US$ Million) Comparison, By Region
4.2.2.2. Market Share Comparison, By Region
4.2.2.3. Y-o-Y growth Comparison, By Region
4.3. Global Market Size and Forecast By Mode of Administration, 2022 to 2032
4.3.1. Injectable Market Size and Forecast, 2022 to 2032
4.3.1.1. Revenue (US$ Million) Comparison, By Region
4.3.1.2. Market Share Comparison, By Region
4.3.1.3. Y-o-Y growth Comparison, By Region
4.3.2. Oral Market Size and Forecast, 2022 to 2032
4.3.2.1. Revenue (US$ Million) Comparison, By Region
4.3.2.2. Market Share Comparison, By Region
4.3.2.3. Y-o-Y growth Comparison, By Region
4.3.3. Others Market Size and Forecast, 2022 to 2032
4.3.3.1. Revenue (US$ Million) Comparison, By Region
4.3.3.2. Market Share Comparison, By Region
4.3.3.3. Y-o-Y growth Comparison, By Region
4.4. Global Market Size and Forecast By Distribution Channel, 2022 to 2032
4.4.1. Hospital Pharmacies Market Size and Forecast, 2022 to 2032
4.4.1.1. Revenue (US$ Million) Comparison, By Region
4.4.1.2. Market Share Comparison, By Region
4.4.1.3. Y-o-Y growth Comparison, By Region
4.4.2. Retail Pharmacies Market Size and Forecast, 2022 to 2032
4.4.2.1. Revenue (US$ Million) Comparison, By Region
4.4.2.2. Market Share Comparison, By Region
4.4.2.3. Y-o-Y growth Comparison, By Region
4.4.3. Online Pharmacies Market Size and Forecast, 2022 to 2032
4.4.3.1. Revenue (US$ Million) Comparison, By Region
4.4.3.2. Market Share Comparison, By Region
4.4.3.3. Y-o-Y growth Comparison, By Region
5. North America Market Size and Forecast, 2022 to 2032
5.1. North America Outlook
5.2. North America Parent Market Outlook
5.3. North America Target Market Outlook
5.4. Revenue (US$ Million) Comparison, By Country
5.4.1. USA Market Size and Forecast (US$ Million), 2022 to 2032
5.4.2. Canada Market Size and Forecast (US$ Million), 2022 to 2032
5.5. Revenue (US$ Million) Comparison, By Indication
5.6. Revenue (US$ Million) Comparison, By Drug Type
5.7. Revenue (US$ Million) Comparison, By Mode of Administration
5.8. Revenue (US$ Million) Comparison, By Distribution Channel
6. Latin America Market Size and Forecast, 2022 to 2032
6.1. Latin America Outlook
6.2. Latin America Parent Market Outlook
6.3. Latin America Target Market Outlook
6.4. Revenue (US$ Million) Comparison, By Country
6.4.1. Brazil Market Size and Forecast (US$ Million), 2022 to 2032
6.4.2. Mexico Market Size and Forecast (US$ Million), 2022 to 2032
6.4.3. Rest of Latin America Market Size and Forecast (US$ Million), 2022 to 2032
6.5. Revenue (US$ Million) Comparison, By Indication
6.6. Revenue (US$ Million) Comparison, By Drug Type
6.7. Revenue (US$ Million) Comparison, By Mode of Administration
6.8. Revenue (US$ Million) Comparison, By Distribution Channel
7. Europe Market Size and Forecast, 2022 to 2032
7.1. Europe Outlook
7.2. Europe Parent Market Outlook
7.3. Europe Target Market Outlook
7.4. Revenue (US$ Million) Comparison, By Country
7.4.1. Germany Market Size and Forecast (US$ Million), 2022 to 2032
7.4.2. United Kingdom Market Size and Forecast (US$ Million), 2022 to 2032
7.4.3. France Market Size and Forecast (US$ Million), 2022 to 2032
7.4.4. Spain Market Size and Forecast (US$ Million), 2022 to 2032
7.4.5. Italy Market Size and Forecast (US$ Million), 2022 to 2032
7.4.6. Rest of Europe Market Size and Forecast (US$ Million), 2022 to 2032
7.5. Revenue (US$ Million) Comparison, By Indication
7.6. Revenue (US$ Million) Comparison, By Drug Type
7.7. Revenue (US$ Million) Comparison, By Mode of Administration
7.8. Revenue (US$ Million) Comparison, By Distribution Channel
8. Japan Market Size and Forecast, 2022 to 2032
8.1. Japan Outlook
8.2. Japan Parent Market Outlook
8.3. Japan Target Market Outlook
8.4. Japan Market Size and Forecast (US$ Million), 2022 to 2032
8.5. Revenue (US$ Million) Comparison, By Indication
8.6. Revenue (US$ Million) Comparison, By Drug Type
8.7. Revenue (US$ Million) Comparison, By Mode of Administration
8.8. Revenue (US$ Million) Comparison, By Distribution Channel
9. APEJ Market Size and Forecast, 2022 to 2032
9.1. Asia Pacific Outlook
9.2. Asia Pacific Parent Market Outlook
9.3. Asia Pacific Target Market Outlook
9.4. Revenue (US$ Million) Comparison, By Country
9.4.1. China Market Size and Forecast (US$ Million), 2022 to 2032
9.4.2. India Market Size and Forecast (US$ Million), 2022 to 2032
9.4.3. Thailand Market Size and Forecast (US$ Million), 2022 to 2032
9.4.4. Singapore Market Size and Forecast (US$ Million), 2022 to 2032
9.4.5. Australia Market Size and Forecast (US$ Million), 2022 to 2032
9.4.6. Rest of APEJ Market Size and Forecast (US$ Million), 2022 to 2032
9.5. Revenue (US$ Million) Comparison, By Indication
9.6. Revenue (US$ Million) Comparison, By Drug Type
9.7. Revenue (US$ Million) Comparison, By Mode of Administration
9.8. Revenue (US$ Million) Comparison, By Distribution Channel
10. MEA Market Size and Forecast, 2022 to 2032
10.1. Middle East and Africa(MEA) Outlook
10.2. Middle East and Africa(MEA) Parent Market Outlook
10.3. Middle East and Africa(MEA) Target Market Outlook
10.4. Revenue (US$ Million) Comparison, By Country
10.4.1. GCC Countries Market Size and Forecast (US$ Million), 2022 to 2032
10.4.2. South Africa Market Size and Forecast (US$ Million), 2022 to 2032
10.4.3. Nigeria Market Size and Forecast (US$ Million), 2022 to 2032
10.4.4. Rest of MEA Market Size and Forecast (US$ Million), 2022 to 2032
10.5. Revenue (US$ Million) Comparison, By Indication
10.6. Revenue (US$ Million) Comparison, By Drug Type
10.7. Revenue (US$ Million) Comparison, By Mode of Administration
10.8. Revenue (US$ Million) Comparison, By Distribution Channel
11. Global Market Company Share, Competition Landscape and Company Profiles
11.1. Global Market Company Share Analysis
11.2. Global Market Competition Landscape
11.3. Global Market Company Profiles
11.3.1. Pfizer Inc.
11.3.2. Allergan Plc
11.3.3. Novartis AG
11.3.4. Bayer Aktiengesellschaft
11.3.5. Medtronic Plc
11.3.6. Sanofi
11.3.7. Johnson & Johnson
11.3.8. Teva Pharmaceutical Industries Limited
11.3.9. Jazz Pharmaceuticals
11.3.10. EMD Serono, Inc.
12. Key Takeaways13. Research Methodology14. Disclaimer
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 01: Global Market Value (US$ Million), 2017 to 2021
Table 02: Global Market Value (US$ Million), 2022 to 2032
Table 03: Global Market Value (US$ Million) and Y-o-Y, 2022 to 2032
Table 04: Global Alzheimer’s Disease Segment Value (US$ Million), By Region 2017 to 2021
Table 05: Global Alzheimer’s Disease Segment Value (US$ Million), By Region 2022 to 2032
Table 06: Global Alzheimer’s Disease Segment Market Share, By Region 2017 to 2021
Table 07: Global Alzheimer’s Disease Segment Market Share, By Region 2022 to 2032
Table 08: Global Alzheimer’s Disease Segment Y-o-Y, By Region 2022 to 2032
Table 09: Global Narcolepsy Segment Value (US$ Million), By Region 2017 to 2021
Table 10: Global Narcolepsy Segment Value (US$ Million), By Region 2022 to 2032
Table 11: Global Narcolepsy Segment Market Share, By Region 2017 to 2021
Table 12: Global Narcolepsy Segment Market Share, By Region 2022 to 2032
Table 13: Global Narcolepsy Segment Y-o-Y, By Region 2022 to 2032
Table 14: Global Multiple Sclerosis Segment Value (US$ Million), By Region 2017 to 2021
Table 15: Global Multiple Sclerosis Segment Value (US$ Million), By Region 2022 to 2032
Table 16: Global Multiple Sclerosis Segment Market Share, By Region 2017 to 2021
Table 17: Global Multiple Sclerosis Segment Market Share, By Region 2022 to 2032
Table 18: Global Multiple Sclerosis Segment Y-o-Y, By Region 2022 to 2032
Table 19: Global Amyotrophic Lateral Sclerosis Segment Value (US$ Million), By Region 2017 to 2021
Table 20: Global Amyotrophic Lateral Sclerosis Segment Value (US$ Million), By Region 2022 to 2032
Table 21: Global Amyotrophic Lateral Sclerosis Segment Market Share, By Region 2017 to 2021
Table 22: Global Amyotrophic Lateral Sclerosis Segment Market Share, By Region 2022 to 2032
Table 23: Global Amyotrophic Lateral Sclerosis Segment Y-o-Y, By Region 2022 to 2032
Table 24: Global Other Indications Segment Value (US$ Million), By Region 2017 to 2021
Table 25: Global Other Indications Segment Value (US$ Million), By Region 2022 to 2032
Table 26: Global Other Indications Segment Market Share, By Region 2017 to 2021
Table 27: Global Other Indications Segment Market Share, By Region 2022 to 2032
Table 28: Global Other Indications Segment Y-o-Y, By Region 2022 to 2032
Table 29: Global Biologics Segment Value (US$ Million), By Region 2017 to 2021
Table 30: Global Biologics Segment Value (US$ Million), By Region 2022 to 2032
Table 31: Global Biologics Segment Market Share, By Region 2017 to 2021
Table 32: Global Biologics Segment Market Share, By Region 2022 to 2032
Table 33: Global Biologics Segment Y-o-Y, By Region 2022 to 2032
Table 34: Global Organic Compounds Segment Value (US$ Million), By Region 2017 to 2021
Table 35: Global Organic Compounds Segment Value (US$ Million), By Region 2022 to 2032
Table 36: Global Organic Compounds Segment Market Share, By Region 2017 to 2021
Table 37: Global Organic Compounds Segment Market Share, By Region 2022 to 2032
Table 38: Global Organic Compounds Segment Y-o-Y, By Region 2022 to 2032
Table 39: Global Injectables Segment Value (US$ Million), By Region 2017 to 2021
Table 40: Global Injectables Segment Value (US$ Million), By Region 2022 to 2032
Table 41: Global Injectables Segment Market Share, By Region 2017 to 2021
Table 42: Global Injectables Segment Market Share, By Region 2022 to 2032
Table 43: Global Injectables Segment Y-o-Y, By Region 2022 to 2032
Table 44: Global Oral Segment Value (US$ Million), By Region 2017 to 2021
Table 45: Global Oral Segment Value (US$ Million), By Region 2022 to 2032
Table 46: Global Oral Segment Market Share, By Region 2017 to 2021
Table 47: Global Oral Segment Market Share, By Region 2022 to 2032
Table 48: Global Oral Segment Y-o-Y, By Region 2022 to 2032
Table 49: Global Others Segment Value (US$ Million), By Region 2017 to 2021
Table 50: Global Others Segment Value (US$ Million), By Region 2022 to 2032
Table 51: Global Others Segment Market Share, By Region 2017 to 2021
Table 52: Global Others Segment Market Share, By Region 2022 to 2032
Table 53: Global Others Segment Y-o-Y, By Region 2022 to 2032
Table 54: Global Hospital Pharmacies Segment Value (US$ Million), By Region 2017 to 2021
Table 55: Global Hospital Pharmacies Segment Value (US$ Million), By Region 2022 to 2032
Table 56: Global Hospital Pharmacies Segment Market Share, By Region 2017 to 2021
Table 57: Global Hospital Pharmacies Segment Market Share, By Region 2022 to 2032
Table 58: Global Hospital Pharmacies Segment Y-o-Y, By Region 2022 to 2032
Table 59: Global Retail Pharmacies Segment Value (US$ Million), By Region 2017 to 2021
Table 60: Global Retail Pharmacies Segment Value (US$ Million), By Region 2022 to 2032
Table 61: Global Retail Pharmacies Segment Market Share, By Region 2017 to 2021
Table 62: Global Retail Pharmacies Segment Market Share, By Region 2022 to 2032
Table 63: Global Retail Pharmacies Segment Y-o-Y, By Region 2022 to 2032
Table 64: Global Online Pharmacies Segment Value (US$ Million), By Region 2017 to 2021
Table 65: Global Online Pharmacies Segment Value (US$ Million), By Region 2022 to 2032
Table 66: Global Online Pharmacies Segment Market Share, By Region 2017 to 2021
Table 67: Global Online Pharmacies Segment Market Share, By Region 2022 to 2032
Table 68: Global Online Pharmacies Segment Y-o-Y, By Region 2022 to 2032
Table 69: North America Market Value (US$ Million), By Country 2017 to 2021
Table 70: North America Market Value (US$ Million), By Country 2022 to 2032
Table 70: North America Market Value (US$ Million), By Indication 2017 to 2021
Table 72: North America Market Value (US$ Million), By Indication 2022 to 2032
Table 73: North America Market Value (US$ Million), By Drug Type 2017 to 2021
Table 74: North America Market Value (US$ Million), By Drug Type 2022 to 2032
Table 75: North America Market Value (US$ Million), By Mode of Administration 2017 to 2021
Table 76: North America Market Value (US$ Million), By Mode of Administration 2022 to 2032
Table 77: North America Market Value (US$ Million), By Distribution Channel 2017 to 2021
Table 78: North America Market Value (US$ Million), By Distribution Channel 2022 to 2032
Table 79: Latin America Market Value (US$ Million), By Country 2017 to 2021
Table 80: Latin America Market Value (US$ Million), By Country 2022 to 2032
Table 81: Latin America Market Value (US$ Million), By Indication 2017 to 2021
Table 82: Latin America Market Value (US$ Million), By Indication 2022 to 2032
Table 83: Latin America Market Value (US$ Million), By Drug Type 2017 to 2021
Table 84: Latin America Market Value (US$ Million), By Drug Type 2022 to 2032
Table 85: Latin America Market Value (US$ Million), By Mode of Administration 2017 to 2021
Table 86: Latin America Market Value (US$ Million), By Mode of Administration 2022 to 2032
Table 87: Latin America Market Value (US$ Million), By Distribution Channel 2017 to 2021
Table 88: Latin America Market Value (US$ Million), By Distribution Channel 2022 to 2032
Table 89: Europe Market Value (US$ Million), By Country 2017 to 2021
Table 90: Europe Market Value (US$ Million), By Country 2022 to 2032
Table 91: Europe Market Value (US$ Million), By Indication 2017 to 2021
Table 92: Europe Market Value (US$ Million), By Indication 2022 to 2032
Table 93: Europe Market Value (US$ Million), By Drug Type 2017 to 2021
Table 94: Europe Market Value (US$ Million), By Drug Type 2022 to 2032
Table 95: Europe Market Value (US$ Million), By Mode of Administration 2017 to 2021
Table 96: Europe Market Value (US$ Million), By Mode of Administration 2022 to 2032
Table 97: Europe Market Value (US$ Million), By Distribution Channel 2017 to 2021
Table 98: Europe Market Value (US$ Million), By Distribution Channel 2022 to 2032
Table 99: Japan Market Value (US$ Million), By Country 2017 to 2021
Table 100: Japan Market Value (US$ Million), By Country 2022 to 2032
Table 101: Japan Market Value (US$ Million), By Indication 2017 to 2021
Table 102: Japan Market Value (US$ Million), By Indication 2022 to 2032
Table 103: Japan Market Value (US$ Million), By Drug Type 2017 to 2021
Table 104: Japan Market Value (US$ Million), By Drug Type 2022 to 2032
Table 105: Japan Market Value (US$ Million), By Mode of Administration 2017 to 2021
Table 106: Japan Market Value (US$ Million), By Mode of Administration 2022 to 2032
Table 107: Japan Market Value (US$ Million), By Distribution Channel 2017 to 2021
Table 108: Japan Market Value (US$ Million), By Distribution Channel 2022 to 2032
Table 109: APEJ Market Value (US$ Million), By Country 2017 to 2021
Table 110: APEJ Market Value (US$ Million), By Country 2022 to 2032
Table 111: APEJ Market Value (US$ Million), By Indication 2017 to 2021
Table 112: APEJ Market Value (US$ Million), By Indication 2022 to 2032
Table 113: APEJ Market Value (US$ Million), By Drug Type 2017 to 2021
Table 114: APEJ Market Value (US$ Million), By Drug Type 2022 to 2032
Table 115: APEJ Market Value (US$ Million), By Mode of Administration 2017 to 2021
Table 116: APEJ Market Value (US$ Million), By Mode of Administration 2022 to 2032
Table 117: APEJ Market Value (US$ Million), By Distribution Channel 2017 to 2021
Table 118: APEJ Market Value (US$ Million), By Distribution Channel 2022 to 2032
Table 119: MEA Market Value (US$ Million), By Country 2017 to 2021
Table 120: MEA Market Value (US$ Million), By Country 2022 to 2032
Table 121: MEA Market Value (US$ Million), By Indication 2017 to 2021
Table 122: MEA Market Value (US$ Million), By Indication 2022 to 2032
Table 123: MEA Market Value (US$ Million), By Drug Type 2017 to 2021
Table 124: MEA Market Value (US$ Million), By Drug Type 2022 to 2032
Table 125: MEA Market Value (US$ Million), By Mode of Administration 2017 to 2021
Table 126: MEA Market Value (US$ Million), By Mode of Administration 2022 to 2032
Table 127: MEA Market Value (US$ Million), By Distribution Channel 2017 to 2021
Table 128: MEA Market Value (US$ Million), By Distribution Channel 2022 to 2032
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 01: Global Market Value (US$ Million), 2017 to 2021
Figure 02: Global Market Value (US$ Million) Forecast, 2022 to 2032
Figure 03: Global Market Value (US$ Million) and Y-o-Y, 2022 to 2032
Figure 04: Global Alzheimer’s Disease Segment Market Value (US$ Million) By Region, 2017 to 2021
Figure 05: Global Alzheimer’s Disease Segment Market Value (US$ Million) By Region, 2022 to 2032
Figure 06: Global Alzheimer’s Disease Segment Y-o-Y Growth Rate, By Region, 2022 to 2032
Figure 07: Global Narcolepsy Segment Market Value (US$ Million) By Region, 2017 to 2021
Figure 08: Global Narcolepsy Segment Market Value (US$ Million) By Region, 2022 to 2032
Figure 09: Global Narcolepsy Segment Y-o-Y Growth Rate, By Region, 2022 to 2032
Figure 10: Global Multiple Sclerosis Segment Market Value (US$ Million) By Region, 2017 to 2021
Figure 11: Global Multiple Sclerosis Segment Market Value (US$ Million) By Region, 2022 to 2032
Figure 12: Global Multiple Sclerosis Segment Y-o-Y Growth Rate, By Region, 2022 to 2032
Figure 13: Global Amyotrophic Lateral Sclerosis Segment Market Value (US$ Million) By Region, 2017 to 2021
Figure 14: Global Amyotrophic Lateral Sclerosis Segment Market Value (US$ Million) By Region, 2022 to 2032
Figure 15: Global Amyotrophic Lateral Sclerosis Segment Y-o-Y Growth Rate, By Region, 2022 to 2032
Figure 16: Global Other Indications Segment Market Value (US$ Million) By Region, 2017 to 2021
Figure 17: Global Other Indications Segment Market Value (US$ Million) By Region, 2022 to 2032
Figure 18: Global Other Indications Segment Y-o-Y Growth Rate, By Region, 2022 to 2032
Figure 19: Global Biologics Segment Market Value (US$ Million) By Region, 2017 to 2021
Figure 20: Global Biologics Segment Market Value (US$ Million) By Region, 2022 to 2032
Figure 21: Global Biologics Segment Y-o-Y Growth Rate, By Region, 2022 to 2032
Figure 22: Global Organic Compounds Segment Market Value (US$ Million) By Region, 2017 to 2021
Figure 23: Global Organic Compounds Segment Market Value (US$ Million) By Region, 2022 to 2032
Figure 24: Global Organic Compounds Segment Y-o-Y Growth Rate, By Region, 2022 to 2032
Figure 25: Global Injectables Segment Market Value (US$ Million) By Region, 2017 to 2021
Figure 26: Global Injectables Segment Market Value (US$ Million) By Region, 2022 to 2032
Figure 27: Global Injectables Segment Y-o-Y Growth Rate, By Region, 2022 to 2032
Figure 28: Global Oral Segment Market Value (US$ Million) By Region, 2017 to 2021
Figure 29: Global Oral Segment Market Value (US$ Million) By Region, 2022 to 2032
Figure 30: Global Oral Segment Y-o-Y Growth Rate, By Region, 2022 to 2032
Figure 31: Global Others Segment Market Value (US$ Million) By Region, 2017 to 2021
Figure 32: Global Others Segment Market Value (US$ Million) By Region, 2022 to 2032
Figure 33: Global Others Segment Y-o-Y Growth Rate, By Region, 2022 to 2032
Figure 34: Global Hospital Pharmacies Segment Market Value (US$ Million) By Region, 2017 to 2021
Figure 35: Global Hospital Pharmacies Segment Market Value (US$ Million) By Region, 2022 to 2032
Figure 36: Global Hospital Pharmacies Segment Y-o-Y Growth Rate, By Region, 2022 to 2032
Figure 37: Global Retail Pharmacies Segment Market Value (US$ Million) By Region, 2017 to 2021
Figure 38: Global Retail Pharmacies Segment Market Value (US$ Million) By Region, 2022 to 2032
Figure 39: Global Retail Pharmacies Segment Y-o-Y Growth Rate, By Region, 2022 to 2032
Figure 40: Global Online Pharmacies Segment Market Value (US$ Million) By Region, 2017 to 2021
Figure 41: Global Online Pharmacies Segment Market Value (US$ Million) By Region, 2022 to 2032
Figure 42: Global Online Pharmacies Segment Y-o-Y Growth Rate, By Region, 2022 to 2032
Figure 43: North America Market Value (US$ Million), By Country 2017 to 2021
Figure 44: North America Market Value (US$ Million), By Country 2022 to 2032
Figure 45: North America Market Value (US$ Million), By Indication 2017 to 2021
Figure 46: North America Market Value (US$ Million), By Indication 2022 to 2032
Figure 47: North America Market Value (US$ Million), By Drug Type 2017 to 2021
Figure 48: North America Market Value (US$ Million), By Drug Type 2022 to 2032
Figure 49: North America Market Value (US$ Million), By Mode of Administration 2017 to 2021
Figure 50: North America Market Value (US$ Million), By Mode of Administration 2022 to 2032
Figure 51: North America Market Value (US$ Million), By Distribution Channel 2017 to 2021
Figure 52: North America Market Value (US$ Million), By Distribution Channel 2022 to 2032
Figure 53: Latin America Market Value (US$ Million), By Country 2017 to 2021
Figure 54: Latin America Market Value (US$ Million), By Country 2022 to 2032
Figure 55: Latin America Market Value (US$ Million), By Indication 2017 to 2021
Figure 56: Latin America Market Value (US$ Million), By Indication 2022 to 2032
Figure 57: Latin America Market Value (US$ Million), By Drug Type 2017 to 2021
Figure 58: Latin America Market Value (US$ Million), By Drug Type 2022 to 2032
Figure 59: Latin America Market Value (US$ Million), By Mode of Administration 2017 to 2021
Figure 60: Latin America Market Value (US$ Million), By Mode of Administration 2022 to 2032
Figure 61: Latin America Market Value (US$ Million), By Distribution Channel 2017 to 2021
Figure 62: Latin America Market Value (US$ Million), By Distribution Channel 2022 to 2032
Figure 63: Europe Market Value (US$ Million), By Country 2017 to 2021
Figure 64: Europe Market Value (US$ Million), By Country 2022 to 2032
Figure 65: Europe Market Value (US$ Million), By Indication 2017 to 2021
Figure 66: Europe Market Value (US$ Million), By Indication 2022 to 2032
Figure 67: Europe Market Value (US$ Million), By Drug Type 2017 to 2021
Figure 68: Europe Market Value (US$ Million), By Drug Type 2022 to 2032
Figure 69: Europe Market Value (US$ Million), By Mode of Administration 2017 to 2021
Figure 70: Europe Market Value (US$ Million), By Mode of Administration 2022 to 2032
Figure 71: Europe Market Value (US$ Million), By Distribution Channel 2017 to 2021
Figure 72: Europe Market Value (US$ Million), By Distribution Channel 2022 to 2032
Figure 73: Japan Market Value (US$ Million), By Country 2017 to 2021
Figure 74: Japan Market Value (US$ Million), By Country 2022 to 2032
Figure 75: Japan Market Value (US$ Million), By Indication 2017 to 2021
Figure 76: Japan Market Value (US$ Million), By Indication 2022 to 2032
Figure 77: Japan Market Value (US$ Million), By Mode of Administration 2017 to 2021
Figure 78: Japan Market Value (US$ Million), By Drug Type 2022 to 2032
Figure 79: Japan Market Value (US$ Million), By Mode of Administration 2017 to 2021
Figure 80: Japan Market Value (US$ Million), By Mode of Administration 2022 to 2032
Figure 81: Japan Market Value (US$ Million), By Distribution Channel 2017 to 2021
Figure 82: Japan Market Value (US$ Million), By Distribution Channel 2022 to 2032
Figure 83: APEJ Market Value (US$ Million), By Country 2017 to 2021
Figure 84: APEJ Market Value (US$ Million), By Country 2022 to 2032
Figure 85: APEJ Market Value (US$ Million), By Indication 2017 to 2021
Figure 86: APEJ Market Value (US$ Million), By Indication 2022 to 2032
Figure 87: APEJ Market Value (US$ Million), By Drug Type 2017 to 2021
Figure 88: APEJ Market Value (US$ Million), By Drug Type 2022 to 2032
Figure 89: APEJ Market Value (US$ Million), By Mode of Administration 2017 to 2021
Figure 90: APEJ Market Value (US$ Million), By Mode of Administration 2022 to 2032
Figure 91: APEJ Market Value (US$ Million), By Distribution Channel 2017 to 2021
Figure 92: APEJ Market Value (US$ Million), By Distribution Channel 2022 to 2032
Figure 93: MEA Market Value (US$ Million), By Country 2017 to 2021
Figure 94: MEA Market Value (US$ Million), By Country 2022 to 2032
Figure 95: MEA Market Value (US$ Million), By Indication 2017 to 2021
Figure 96: MEA Market Value (US$ Million), By Indication 2022 to 2032
Figure 97: MEA Market Value (US$ Million), By Drug Type 2017 to 2021
Figure 98: MEA Market Value (US$ Million), By Drug Type 2022 to 2032
Figure 99: MEA Market Value (US$ Million), By Mode of Administration 2017 to 2021
Figure 100: MEA Market Value (US$ Million), By Mode of Administration 2022 to 2032
Figure 101: MEA Market Value (US$ Million), By Distribution Channel 2017 to 2021
Figure 102: MEA Market Value (US$ Million), By Distribution Channel 2022 to 2032
